Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation (Q33393107)

26 July 2017

Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation (English)

1 reference

26 July 2017

Samhar I Al-Akash

1

1 reference

26 July 2017

P Stephen Almond

2

1 reference

26 July 2017

Van H Savell

3

1 reference

26 July 2017

Salam I Gharaybeh

4

1 reference

26 July 2017

Cris Hogue

5

1 reference

26 July 2017

language of work or name

1 reference

2 December 2010

1 reference

26 July 2017

1 reference

26 July 2017

26

1 reference

26 July 2017

613-619

1 reference

26 July 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1007/s00467-010-1708-6

26 July 2017

0 references

cites work

Renal transplantation in HUS patients with disorders of complement regulation

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Autosomal dominant hemolytic uremic syndrome: variable phenotypes and transplant results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Genetics and complement in atypical HUS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Hemolytic uremic syndrome recurrence after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Fulminant recurrence of atypical hemolytic uremic syndrome during a calcineurin inhibitor-free immunosuppression regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Letter: Haemolytic-uraemic syndrome: evidence for intravascular C3 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Familial haemolytic uraemic syndrome and an MCP mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Thrombomodulin mutations in atypical hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Atypical hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Recurrence of hemolytic-uremic syndrome in renal transplant recipients: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Successful plasma therapy in hemolytic uremic syndrome with factor H deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Secondary failure of plasma therapy in factor H deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Eculizumab for congenital atypical hemolytic-uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Complement inhibitor eculizumab in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

Eculizumab for Atypical Hemolytic–Uremic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1708-6

21 January 2018

1 reference

12 December 2020

Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome

1 reference

12 December 2020

Genetic studies into inherited and sporadic hemolytic uremic syndrome

1 reference

12 December 2020

Human complement factor H deficiency associated with hemolytic uremic syndrome.

1 reference

12 December 2020

Hemolytic uremic syndrome with hypocomplementemia, serum C3NeF, and glomerular deposits of C3

1 reference

12 December 2020

Atypical relapse of hemolytic uremic syndrome after transplantation

1 reference

12 December 2020

Atypical hemolytic uremic syndrome associated with H1N1 influenza A virus infection

1 reference

12 December 2020

Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H.

1 reference

12 December 2020

10.1007/S00467-010-1708-6

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1002434817

0 references

Fatcat ID

release_2tidxg72zvgtxkeihctb2c6tmy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2tidxg72zvgtxkeihctb2c6tmy

24 November 2022

mapped directly with Wikidata item

1 reference